Breast CancerFDA Approvals, News & Updates

Kadcyla Approved for Adjuvant Treatment of HER2-Positive Early Breast Cancer with Residual Invasive Disease

June 2019 Vol 5 No 3

In May 2019, the FDA approved a new indication for Kadcyla (ado-trastuzumab emtansine; from Genentech) for adjuvant (additional) treatment of patients with HER2-positive early breast cancer and residual invasive disease after endocrine treatment with a taxane and Herceptin (trastuzumab). At the same time, the FDA approved 2 tests that should be used to select appropriate patients for adjuvant treatment with Kadcyla. Kadcyla was initially approved in 2013 for HER2-positive metastatic breast cancer.

This new approval was based on a clinical trial of 1486 patients with HER2-positive early breast cancer who received Kadcyla or Herceptin for a total of 14 cycles. After an average of 40 months, patients who received Kadcyla showed significant reduction in residual invasive disease versus those who received Herceptin. The most common side effects with Kad­cyla are fatigue, nausea, musculoskeletal and joint pain, bleeding, low platelet count, headache, and peripheral neuropathy.

Recommended For You
Breast Cancer
Drugs for Breast Cancer
Here are the drugs and financial support services available to patients receiving treatment for Breast Cancer.
Breast CancerHero of Hope
How My Nurse Navigator Helped Me
By Kirsten Arbon
2019 Hero of Hope Patient Award winner Kirstin Arbon explains how her nurse navigator provided her with guidance, wisdom, and support during her cancer journey.
Last modified: July 15, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.